HighPoint Advisor Group’s Acadia Pharmaceuticals ACAD Stock Holding History

HighPoint Advisor Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$235K	Sell	14,160 -1,145	-7%	-$22.1K	0.02%	463
2021 Q2	$373K	Buy	15,305 +516	+3%	+$11.6K	0.04%	355
2021 Q1	$302K	Buy	14,789 +600	+4%	+$26.4K	0.03%	368
2020 Q4	$716K	Buy	14,189 +5,018	+55%	+$249K	0.09%	188
2020 Q3	$445K	Buy	+9,171	New	+$396K	0.08%	203
2017 Q1	–	Sell	-29,980	Closed	-$1.1M	–	279
2016 Q4	$1.1M	Buy	+29,980	New	+$793K	0.35%	69

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HighPoint Advisor Group's ACAD Position: Q3 2021 in Review

HighPoint Advisor Group reduced its Acadia Pharmaceuticals (ACAD) stake by 7.5% in Q3 2021, selling an estimated $22.1K and leaving 14,160 shares worth $235K. The position accounts for 0.02% of the portfolio, ranked #463.

HighPoint Advisor Group first reported a position in ACAD in Q4 2016 and has held it in 6 quarters since. The position peaked at $1.1M in Q4 2016. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

HighPoint Advisor Group held 14,160 shares of Acadia Pharmaceuticals worth $235K as of Q3 2021.
HighPoint Advisor Group sold 1,145 Acadia Pharmaceuticals shares in Q3 2021, an estimated $22.1K.
Acadia Pharmaceuticals made up 0.02% of HighPoint Advisor Group's portfolio in Q3 2021, its #463 holding.
HighPoint Advisor Group first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 6 quarters since.
HighPoint Advisor Group's Acadia Pharmaceuticals position peaked at $1.1M in Q4 2016.
237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on HighPoint Advisor Group's 13F filing for Q3 2021, filed 15 Nov 2021.